These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18651118)

  • 21. Recent clinical studies of the effects of lipid-modifying therapies.
    Gotto AM; Moon JE
    Am J Cardiol; 2012 Jul; 110(1 Suppl):15A-26A. PubMed ID: 22697388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prevention of myocardial infarcts. Facts and myths].
    Stiefelhagen P
    MMW Fortschr Med; 2006 May; 148(18):4-6, 8. PubMed ID: 16736675
    [No Abstract]   [Full Text] [Related]  

  • 23. [Prevention of recurrence of acute coronary syndrome].
    Aihara K; Daida H
    Nihon Naika Gakkai Zasshi; 2004 Feb; 93(2):287-94. PubMed ID: 15007936
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
    Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
    Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary prevention of atherothrombotic cerebrovascular events.
    Paciaroni M
    Curr Vasc Pharmacol; 2014 May; 12(3):365-72. PubMed ID: 24846225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?
    Jankowski P; Czarnecka D; Lysek R; Skrzek A; Smaś-Suska M; Mazurek A; Brzozowska-Kiszka M; Wolfshaut-Wolak R; Surowiec S; Bogacki P; Bryniarska-Mirek E; Bryniarski L; Grodecki J; Nessler J; Olszowska M; Podolec P; Kawecka-Jaszcz K; Pająk A
    Kardiol Pol; 2014; 72(4):355-62. PubMed ID: 24408064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
    Bourassa MG; Berry C
    Curr Atheroscler Rep; 2008 Apr; 10(2):106-16. PubMed ID: 18417064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors.
    Kaski JC; Fernandez-Berges D
    Cardiovasc Drugs Ther; 2008 Jun; 22(3):185-91. PubMed ID: 18317916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aggressive lipid therapy in the statin era.
    Farmer JA
    Prog Cardiovasc Dis; 1998; 41(2):71-94. PubMed ID: 9790411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice.
    Heeley E; Anderson C; Patel A; Cass A; Peiris D; Weekes A; Chalmers J
    Int J Stroke; 2012 Dec; 7(8):649-54. PubMed ID: 21978147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey].
    Jullien G; Mosnier M; Danchin N
    Ann Cardiol Angeiol (Paris); 2005 Aug; 54(4):184-9. PubMed ID: 16104618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
    Aronow WS
    J Gerontol A Biol Sci Med Sci; 2003 Oct; 58(10):M927-33. PubMed ID: 14570861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL;
    Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evaluation of short and long-term administration of drugs improving life expectancy in patients with myocardial infarction in a Hungarian county hospital.
    Márk L; Dani G; Nagy E; Erdei F; Katona A
    Cent Eur J Public Health; 2006 Mar; 14(1):6-9. PubMed ID: 16705873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence-based medical therapy of patients with acute coronary syndromes.
    Ramanath VS; Eagle KA
    Am J Cardiovasc Drugs; 2007; 7(2):95-116. PubMed ID: 17503881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary prevention following myocardial infarction: a clinical update.
    Isted A; Williams R; Oakeshott P
    Br J Gen Pract; 2018 Mar; 68(668):151-152. PubMed ID: 29472228
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.